
Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
Treatment with nivolumab (Opvido; Bristol Myers Squibb) after chimeric antigen receptor (CAR) T-cell therapy may restore T-cell fitness in patients with relapsed, refractory multiple myeloma (RRMM), according to a study published in Blood Advances. These …